Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine.

BACKGROUND: Herpesvirus of turkey (HVT) as a vector to express the haemagglutinin (HA) of avian influenza virus (AIV) H5 was developed and its protection against lethal Marek's disease virus (MDV) and highly pathogenic AIV (HPAIV) challenges was evaluated previously. It is well-known that aviru...

Full description

Bibliographic Details
Main Authors: Hongyu Cui, Hongbo Gao, Xianlan Cui, Yan Zhao, Xingming Shi, Qiaoling Li, Shuai Yan, Ming Gao, Mei Wang, Changjun Liu, Yunfeng Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3536743?pdf=render
id doaj-7b150d208b52434a9d6f214fdf164c40
record_format Article
spelling doaj-7b150d208b52434a9d6f214fdf164c402020-11-25T00:12:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0181e5334010.1371/journal.pone.0053340Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine.Hongyu CuiHongbo GaoXianlan CuiYan ZhaoXingming ShiQiaoling LiShuai YanMing GaoMei WangChangjun LiuYunfeng WangBACKGROUND: Herpesvirus of turkey (HVT) as a vector to express the haemagglutinin (HA) of avian influenza virus (AIV) H5 was developed and its protection against lethal Marek's disease virus (MDV) and highly pathogenic AIV (HPAIV) challenges was evaluated previously. It is well-known that avirulemt MDV type 1 vaccines are more effective than HVT in prevention of lethal MDV infection. To further increase protective efficacy against HPAIV and lethal MDV, a recombinant MDV type 1 strain 814 was developed to express HA gene of HPAIV H5N1. METHODOLOGY/PRINCIPAL FINDINGS: A recombinant MDV-1 strain 814 expressing HA gene of HPAIV H5N1 virus A/goose/Guangdong/3/96 at the US2 site (rMDV-HA) was developed under the control of a human CMV immediate-early promoter. The HA expression in the rMDV-HA was tested by immunofluorescence and Western blot analyses, and in vitro and in vivo growth properties of rMDV-HA were also analyzed. Furthermore, we evaluated and compared the protective immunity of rMDV-HA and previously constructed rHVT-HA against HPAIV and lethal MDV. Vaccination of chickens with rMDV-HA induced 80% protection against HPAIV, which was better than the protection rate by rHVT-HA (66.7%). In the animal study with MDV challenge, chickens immunized with rMDV-HA were completely protected against virulent MDV strain J-1 whereas rHVT-HA only induced 80% protection with the same challenge dose. CONCLUSIONS/SIGNIFICANCE: The rMDV-HA vaccine was more effective than rHVT-HA vaccine for protection against lethal MDV and HPAIV challenges. Therefore, avirulent MDV type 1 vaccine is a better vector than HVT for development of a recombinant live virus vaccine against virulent MDV and HPAIV in poultry.http://europepmc.org/articles/PMC3536743?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Hongyu Cui
Hongbo Gao
Xianlan Cui
Yan Zhao
Xingming Shi
Qiaoling Li
Shuai Yan
Ming Gao
Mei Wang
Changjun Liu
Yunfeng Wang
spellingShingle Hongyu Cui
Hongbo Gao
Xianlan Cui
Yan Zhao
Xingming Shi
Qiaoling Li
Shuai Yan
Ming Gao
Mei Wang
Changjun Liu
Yunfeng Wang
Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine.
PLoS ONE
author_facet Hongyu Cui
Hongbo Gao
Xianlan Cui
Yan Zhao
Xingming Shi
Qiaoling Li
Shuai Yan
Ming Gao
Mei Wang
Changjun Liu
Yunfeng Wang
author_sort Hongyu Cui
title Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine.
title_short Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine.
title_full Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine.
title_fullStr Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine.
title_full_unstemmed Avirulent Marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine.
title_sort avirulent marek's disease virus type 1 strain 814 vectored vaccine expressing avian influenza (ai) virus h5 haemagglutinin induced better protection than turkey herpesvirus vectored ai vaccine.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description BACKGROUND: Herpesvirus of turkey (HVT) as a vector to express the haemagglutinin (HA) of avian influenza virus (AIV) H5 was developed and its protection against lethal Marek's disease virus (MDV) and highly pathogenic AIV (HPAIV) challenges was evaluated previously. It is well-known that avirulemt MDV type 1 vaccines are more effective than HVT in prevention of lethal MDV infection. To further increase protective efficacy against HPAIV and lethal MDV, a recombinant MDV type 1 strain 814 was developed to express HA gene of HPAIV H5N1. METHODOLOGY/PRINCIPAL FINDINGS: A recombinant MDV-1 strain 814 expressing HA gene of HPAIV H5N1 virus A/goose/Guangdong/3/96 at the US2 site (rMDV-HA) was developed under the control of a human CMV immediate-early promoter. The HA expression in the rMDV-HA was tested by immunofluorescence and Western blot analyses, and in vitro and in vivo growth properties of rMDV-HA were also analyzed. Furthermore, we evaluated and compared the protective immunity of rMDV-HA and previously constructed rHVT-HA against HPAIV and lethal MDV. Vaccination of chickens with rMDV-HA induced 80% protection against HPAIV, which was better than the protection rate by rHVT-HA (66.7%). In the animal study with MDV challenge, chickens immunized with rMDV-HA were completely protected against virulent MDV strain J-1 whereas rHVT-HA only induced 80% protection with the same challenge dose. CONCLUSIONS/SIGNIFICANCE: The rMDV-HA vaccine was more effective than rHVT-HA vaccine for protection against lethal MDV and HPAIV challenges. Therefore, avirulent MDV type 1 vaccine is a better vector than HVT for development of a recombinant live virus vaccine against virulent MDV and HPAIV in poultry.
url http://europepmc.org/articles/PMC3536743?pdf=render
work_keys_str_mv AT hongyucui avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT hongbogao avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT xianlancui avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT yanzhao avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT xingmingshi avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT qiaolingli avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT shuaiyan avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT minggao avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT meiwang avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT changjunliu avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
AT yunfengwang avirulentmareksdiseasevirustype1strain814vectoredvaccineexpressingavianinfluenzaaivirush5haemagglutinininducedbetterprotectionthanturkeyherpesvirusvectoredaivaccine
_version_ 1725400182561964032